NCT06404840View on ClinicalTrials.gov

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

nimotuzumab

nimotuzumab (400 mg, iv, d1, qw)

DRUG

AG chemotherapy

(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)

Trial Locations (1)

300308

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER